Used primarily in cancer research, it targets the methionine adenosyltransferase 2A (MAT2A) enzyme, which plays a critical role in methionine metabolism. By inhibiting this enzyme, it disrupts the production of S-adenosylmethionine (SAM), a key methyl donor essential for cancer cell growth and survival. This makes it a promising candidate for treating cancers with methylthioadenosine phosphorylase (MTAP) deletion, a common genetic alteration in certain tumors. Its application is being explored in preclinical studies to evaluate its efficacy in reducing tumor growth and improving therapeutic outcomes. Additionally, it is investigated for its potential to enhance the effectiveness of other anticancer therapies when used in combination.